|
Neonatal Intensive Care Drug Manual
|
| bet | 235/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Special comments
|
|
Evidence
|
Efficacy and safety:
Symptomatic congenital cytomegalovirus disease: A randomised, controlled trial in infants ≥ 32 weeks GA of 6 weeks IV ganciclovir 6 mg/kg every 12 hours demonstrated more infants had improved hearing or maintained normal hearing between baseline and 6 months in the IV ganciclovir group versus placebo (84% vs 59%, p = 0.06) and fewer infants had worsening hearing (0% vs 41%, p < 0.01).1 This effect was sustained at 1 year of age, when 21% of infants in the treatment group had worsening hearing versus 68% in the placebo group (p < 0.01)1. Two-thirds of the treatment group developed significant neutropenia1. At 12 months, infants treated with 6 weeks IV ganciclovir had fewer developmental delays.2 [LOE II, GOR B – see below for recommendation].
There are reports of the use of 10–12 mg/kg/day in 2 divided doses in extreme preterm infants.10-14
|
|
| |
